The Clinical Impact of Time to Response in De Novo Accelerated-Phase Chronic Myeloid Leukemia.

Please login or register to bookmark this article
Bookmark this %label%

We aimed to describe the impact of time to response on the outcomes of 75 patients with accelerated-phase chronic myeloid leukemia (CML-AP) at diagnosis. Patients had at least 1 feature of AP: blasts ≥ 15% (n = 2), basophils ≥ 20% (n = 19), platelets

Click here to read the full article @ American journal of hematology